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The autosomal recessive neurodegenerative disease spinal muscular atrophy (SMA) results from low levels 
of survival motor neuron (SMN) protein; however, it is unclear how reduced SMN promotes SMA develop-
ment. Here, we determined that ubiquitin-dependent pathways regulate neuromuscular pathology in SMA. 
Using mouse models of SMA, we observed widespread perturbations in ubiquitin homeostasis, including 
reduced levels of ubiquitin-like modifier activating enzyme 1 (UBA1). SMN physically interacted with UBA1 
in neurons, and disruption of Uba1 mRNA splicing was observed in the spinal cords of SMA mice exhibiting 
disease symptoms. Pharmacological or genetic suppression of UBA1 was sufficient to recapitulate an SMA-
like neuromuscular pathology in zebrafish, suggesting that UBA1 directly contributes to disease pathogenesis. 
Dysregulation of UBA1 and subsequent ubiquitination pathways led to β-catenin accumulation, and pharma-
cological inhibition of β-catenin robustly ameliorated neuromuscular pathology in zebrafish, Drosophila, and 
mouse models of SMA. UBA1-associated disruption of β-catenin was restricted to the neuromuscular system 
in SMA mice; therefore, pharmacological inhibition of β-catenin in these animals failed to prevent systemic 
pathology in peripheral tissues and organs, indicating fundamental molecular differences between neuromus-
cular and systemic SMA pathology. Our data indicate that SMA-associated reduction of UBA1 contributes to 
neuromuscular pathogenesis through disruption of ubiquitin homeostasis and subsequent β-catenin signal-
ing, highlighting ubiquitin homeostasis and β-catenin as potential therapeutic targets for SMA.
Introduction
Proximal spinal muscular atrophy (SMA) is the leading genetic cause 
of infant mortality, with a carrier frequency of 1 in 35 in the popula-
tion of mixed European descent and an incidence of approximately 
1 in 6,000–10,000 live births (1, 2). This autosomal recessive neuro-
muscular disorder is most commonly caused by homozygous dele-
tion of the survival motor neuron 1 (SMN1) gene, leading to reduced 
levels of ubiquitously expressed full-length SMN protein (1, 3). SMA 
is primarily characterized by degeneration of lower motor neurons 
and atrophy of skeletal muscle (3, 4), with functional and structural 
disruption of synaptic connectivity at neuromuscular junctions 
(NMJ) and in the spinal cord occurring during the early stages of dis-
ease pathogenesis (5–9). However, recent studies have revealed that 
SMA, particularly in its most severe forms, is a multisystem disorder 
(10), with other regions of the nervous system also being affected 
(e.g., the hippocampus; ref. 11) as well as nonneuronal tissues and 
organs, including heart (12), vasculature (13), liver (14), pancreas 
(15), lung, and intestines (16). This suggests that SMN deficiency 
causes perturbations across a wide range of cells and tissues in SMA, 
albeit with motor neurons being the most vulnerable cell type.
Despite a clear understanding of the genetic causes of SMA, the 
mechanisms linking low levels of SMN to disease pathogenesis 
remain unclear. SMN protein is known to play key roles in several 
core canonical cellular pathways, including snRNP biogenesis and 
pre-mRNA splicing (3). However, attempts to link disruptions in 
RNA processing directly to SMA pathogenesis have proven con-
troversial (17–20). The finding that mutations in genes encoding 
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proteins not directly involved in RNA processing can cause related 
diseases (e.g., mutations in BICD2 cause congenital autosomal-
dominant SMA, ref. 21; and mutations in ubiquitin-like modifier 
activating enzyme 1 [UBA1] cause X-linked infantile SMA, ref. 22), 
alongside reports linking SMN protein to actin dynamics (23, 24), 
Phosphatase and tensin homolog–mediated (PTEN-mediated) 
protein synthesis pathways (25), and translational regulation (26), 
suggests that SMN may fulfil additional roles downstream from, or 
outside of, RNA processing pathways in the nucleus and cell body of 
neurons. The identification of key pathways downstream from SMN 
that are critical for the regulation of neuromuscular and system- 
wide pathology in SMA will be important for designing, testing, and 
evaluating new therapeutic approaches for SMA patients.
The studies described here were initiated to identify key molecu-
lar pathways present in the neuronal cytoplasm and acting down-
stream of SMN that are responsible for regulating neuromuscular 
and systemic pathology in SMA. Combining proteomic screens 
with cellular and molecular approaches in mouse, Drosophila, and 
zebrafish models, we reveal widespread disruption to ubiquitin 
homeostasis in SMA, leading to perturbations in β-catenin signal-
ing pathways in the neuromuscular system.
Results
Widespread perturbations in ubiquitin homeostasis in animal models 
of SMA. The initial aim of the study was to identify functional 
molecular pathways modified downstream of SMN depletion in 
SMA. In order to examine neuronal material that was biologi-
cally relevant and yet free from contamination by nuclear and/or 
myelin proteins (the abundance of which can hamper the sensitiv-
ity of proteomics screens), we initially performed unbiased iTRAQ 
comparative proteomics on synapses isolated from the hippocam-
pus of presymptomatic (P1) “severe” SMA mice (Smn–/– SMN2tg/tg) 
compared with littermate controls (Smn+/+ SMN2tg/tg). We chose 
to use hippocampal synaptosomes for these experiments due to 
the known susceptibility of the hippocampus in mouse models of 
SMA (11), as well as the known susceptibility of synaptic compart-
ments of neurons in SMA during the early stages of disease (7, 8). 
Biochemical analysis of isolated synaptic preparations from mice 
confirmed the presence of SMN protein and its known interacting 
proteins (e.g., gemin5) in the synaptic cytoplasm at CNS synapses 
(Supplemental Figures 1 and 2; supplemental material available 
online with this article; doi:10.1172/JCI71318DS1). SMN protein 
was also present in synaptic boutons at the Drosophila NMJ (Sup-
plemental Figures 1 and 2), confirming the biological relevance 
of using synaptic preparations for the initial proteomics screen.
The iTRAQ screen revealed robust disruption of the synaptic 
proteome in SMA mice, where 52 out of 150 (35%) unique pro-
teins identified had expression levels modified by more than 20% 
in SMA mice (Supplemental Tables 1 and 2). Functional cluster-
ing analyses, using IPA software (see Methods), linked these indi-
vidual protein changes to significant modifications in a range of 
canonical functional pathways (Table 1). Interestingly, these analy-
ses highlighted significant disruption to protein ubiquitination 
pathways in SMA mice, with decreased levels of UBA1 (Supple-
mental Figure 3A) and increased levels of ubiquitin carboxyter-
minal esterase L1 (UCHL1) (Table 1 and Supplemental Tables 1 
and 2). Ubiquitination pathways, and UBA1 in particular, were of 
interest in the context of SMA because mutations in the gene cod-
ing for human UBA1 (UBE1) are sufficient to cause a genetically 
distinct form of the disease, known as X-linked infantile SMA (22). 
Moreover, ubiquitination pathways are known to regulate axonal 
and synaptic stability (27) as well as the stability and degradation 
of the SMN protein itself (28–30).
To establish whether disruption of ubiquitin-dependent path-
ways was conserved across the range of cells and tissues present 
in the neuromuscular system, UBA1 protein levels were examined 
in preparations of spinal cord (Figure 1, A and B, and Supplemen-
tal Figure 3B) and skeletal muscle (Figure 1, A and C) from severe 
SMA mice. UBA1 protein levels were reduced approximately 50% 
in SMA mouse spinal cord (Figure 1B) and more than 60% in skel-
etal muscle (gastrocnemius; Figure 1C) at P5.
UBA1 regulates the first stages of an enzymatic cascade in which 
ubiquitin molecules are ultimately conjugated to target proteins; 
therefore, disruption of UBA1 (alongside concomitant changes 
in other ubiquitin-related proteins such as UCHL1) would be 
predicted to affect overall ubiquitin homeostasis. To determine 
whether this occurred in SMA, we measured levels of ubiquitin in 
the spinal cords from severe SMA mice. Levels of both monomeric 
and multimeric ubiquitin were significantly decreased (Figure 1, 
D–F). SMN-dependent perturbations in ubiquitin homeostasis 
were also conserved across other species and tissues, as a dramat-
ic redistribution of mono- and polyubiquitinated proteins was 
observed in striated muscle from an established Drosophila model 
of SMA (Figure 1G and ref. 31).
To determine the time course of UBA1 changes in SMA, we 
examined UBA1 expression in “Taiwanese” SMA mice, which dis-
play a milder phenotype than severe SMA mice (mean survival of 
∼11 days compared with ∼5–6 days; ref. 32). We examined UBA1 
protein expression in motor neuron cell soma located in the ven-
tral horn of spinal cord at presymptomatic (P3) and early symp-
tomatic (P7) stages of disease (Figure 1, H–J). In control mice, 
UBA1 was almost exclusively localized to the neuronal cytoplasm 
at P3, before undergoing a dramatic subcellular relocalization to 
the nucleus by P7 (Figure 1, H and I). There was no overt differ-
ence in UBA1 localization in SMA mice at P3. However, at P7, we 
noted an almost complete absence of UBA1 from the motor neu-
Table 1
Clustering analysis of proteomics data revealing functional pathways modified in P1 SMA mouse synapses
Pathway P value Individual proteins (>20% changed in SMA)
Oxidative phosphorylation 1.61 × 10–07 ATP5A1, ATP5F1, ATP6V1A, COX5A, CYC1, PPA1
Protein ubiquitination 8.59 × 10–06 HSP90AA1, HSP90AB1, HSPA9, HSPD1, PSMD2, UBA1, UCHL1
Glycolysis/gluconeogenesis 1.14 × 10–04 ALDOA, PGAM1, PGK1, PKM2
Purine metabolism 1.15 × 10–04 ATP1B1, ATP5A1, ATP5F1, HSP90AA1, HSPD1, PKM2
PI3K/AKT signaling 3.64 × 10–04 CTNNB1, HSP90AA1, HSP90AB1, YWHAG
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Figure 1
Perturbations in UBA1 levels and 
ubiquitin homeostasis in mouse 
and Drosophila models of SMA. 
(A–C) Significant reduction in lev-
els of UBA1 protein in spinal cord 
and skeletal muscle from severe 
SMA mice at P5 compared with 
littermate controls (con), quanti-
fied using fluorescent Western blot 
(n = 3 mice/genotype; unpaired 
2-tailed t test). (D–F) Reduced 
levels of both monomeric and mul-
timeric ubiquitin in the spinal cord 
of Taiwanese SMA mice at P10 
(tubulin: loading control; n = 3 mice/
genotype). (G) Representative 
confocal micrographs of striated 
muscle from WT and SMA Dro-
sophila larvae immunolabeled with 
an antibody that recognizes mono- 
and polyubiquitinated proteins 
(green). Diffuse staining in muscle 
and muscle nuclei (stained with 
Hoechst, blue) of WT flies contrast-
ed with a distinct lack of nuclear 
staining and increased perinuclear 
staining in SMA flies. Each panel 
in G is 75 μm in length. (H and I) 
UBA1 (green) and NeuN (red) 
immunolabeling of motor neurons 
from Taiwanese SMA and litter-
mate control mouse spinal cords at 
P3 (H) and P7 (I). Note how UBA1 
was predominantly cytoplasmic at 
P3 but nuclear at P7. Scale bars: 
10 μm. (J) Significant increase in 
the ratio of nuclear to cytoplasmic 
UBA1 in SMA motor neurons at P7 
compared with littermate controls 
(n = 24 motor neurons per geno-
type). (K) UBA1 levels in whole spi-
nal cord of Taiwanese SMA mice 
remained unchanged at P3 and 
P7, but were significantly reduced 
by P10 (n > 3 mice per time point/
genotype; ANOVA with Tukey’s 
post-hoc test). (L) Levels of UBA1 
in skeletal muscle were significant-
ly reduced at an early symptomatic 
age (P7) in Taiwanese SMA mice 
(n = 4 mice per genotype). *P < 0.05; 
**P < 0.01; ***P < 0.001.
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Figure 2
UBA1 physically interacts with SMN protein in vivo, and Uba1 splicing is dysregulated at late symptomatic time points in SMA mouse spinal cord. 
(A) No change in levels of Uba1 mRNA (or a control mRNA, Fth1; similar control data using Mapt not shown) in the spinal cord of P5 severe SMA 
mice, quantified using qPCR (n = 3 mice per genotype; ANOVA with Tukey’s post hoc test). (B) Representative fluorescent Western blots for SMN 
(left lane) and UBA1 (right lane) from co-IP experiments on spinal cord extracts from WT mice, using SMN-bound beads, demonstrating that UBA1 
physically interacts with SMN in vivo. (C) Graphic overview of the exon structure of Uba1. Two Uba1 splice variants are generated with unique first 
exons. The position of primers used to amplify each splice variant is highlighted. Note that the coding sequence of Uba1 starts in exon 2. (D–F) Bar 
charts showing relative expression levels of Uba1a and Uba1b, as well as the ratio of Uba1a to Uba1b, in SMA (Taiwanese) and control spinal 
cord at P3 (D; presymptomatic), P7 (E; early symptomatic), and P11 (late-symptomatic) (n = 3 mice per genotype, 3 independent amplifications per 
sample; 2-tailed, unpaired t tests). Uba1 splicing was significantly dysregulated in the late-symptomatic mice. **P < 0.01; ***P < 0.001.
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ron cytoplasm in SMA mice, when low levels persisted in littermate 
control mice (Figure 1I). Quantification of the ratio of nuclear/
cytoplasmic UBA1 levels in SMA mice revealed a significant reduc-
tion in the cytoplasm compared with controls (Figure 1J). Thus, 
redistribution of UBA1 occurring during the early postnatal peri-
od was perturbed in SMA mice at early symptomatic stages of the 
disease. Interestingly, quantification of total UBA1 levels in spi-
nal cord did not reveal a significant reduction in SMA mice until 
late-symptomatic stages (P10; Figure 1K), suggesting that subtle 
changes in the subcellular distribution of UBA1 were perturbed 
in motor neurons in advance of a widespread reduction in pro-
tein levels throughout the spinal cord. Comparable examination 
of UBA1 levels in whole muscle showed a significant loss by P7 
in SMA (Figure 1L), suggesting that muscle may be more severely 
affected than spinal cord.
SMN-Uba1 interactions and dysregulation of Uba1 splicing in SMA. To 
investigate potential pathways through which UBA1 and ubiq-
uitin homeostasis are targeted in SMA, we first asked whether 
changes were occurring due to reduced expression of Uba1 mRNA. 
As mRNA levels for Uba1 remained unchanged in the spinal cords 
of SMA mice (Figure 2A), it was unlikely that UBA1 protein levels 
were reduced as a result of global deficiencies in transcription of 
Uba1 mRNA. Given that SMN protein interacts with other pro-
teins in vitro, including members of the ubiquitin-proteasome sys-
Figure 3
Genetic and pharmacological suppression of uba1 in zebrafish leads to dose-dependent motor axon pathology. (A) Representative fluorescence 
micrographs of motor axons growing out from the spinal cord in a control zebrafish 34 hours after fertilization, and in animals injected with either 
4 ng or 6 ng of a MO suppressing uba1 levels (see Supplemental Figure 4). (B) Representative higher-magnification confocal micrographs show-
ing abnormal sprouts and axonal extensions in motor axons from MO-treated zebrafish. Scale bars: 50 μm. (C) Dose-dependent increase in the 
occurrence of abnormal branching in MO-treated zebrafish (Kruskal-Wallis test with Dunn’s post hoc test; uninjected, n = 310 motor neurons, 
n = 31 animals; 4 ng, n = 360, n = 36 animals; 6 ng, n = 360, n = 36 animals). Only motor axons with modest (type 2; see Supplemental Figure 4) 
or severely abnormal branching (type 3; see Supplemental Figure 4) were quantified as having abnormal branching. (D) Representative confo-
cal micrographs showing perturbations in motor axon morphology in Tg(hb9:gfp) zebrafish embryos treated with 50 μM of the UBA1 inhibitor 
UBEI-41. Note the presence of a “double-exit” motor axon (right hand side of image) in the UBEI-41 example, with the axon branch emerging on 
the right side of the pair showing stunted outgrowth. Scale bars: 100 μm; 30 μm (B, D). (E) Levels of abnormal motor axon branching and axon 
outgrowth in UBEI-41–treated zebrafish. Note the dose-dependent increase of numbers of aberrant motor axons in the UBEI-41 group compared 
with DMSO controls (10 μM UBEI-41 n = 258 nerves, n = 11 animals; 50 μM UBEI-41 n = 280 nerves n = 12 animals; Kruskal-Wallis test with 
Dunn’s post hoc test). ***P < 0.001.
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tem such as UCHL1 (29, 30), we next wanted to determine whether 
SMN could be influencing UBA1 levels as a result of direct physi-
cal interactions in vivo. We therefore performed coimmunoprecip-
itation (co-IP) experiments on spinal cord extracts from WT mice, 
using anti-SMN beads. Immunoblotting on the bound extract 
with antibodies against UBA1 revealed that UBA1 and SMN physi-
cally interact in the neuronal cytoplasm in vivo (Figure 2B).
Several recent studies have also implicated SMN in the regu-
lation of splicing; therefore, we next analyzed splicing patterns 
for Uba1 in the spinal cords of Taiwanese SMA mice at presymp-
tomatic (P3), early symptomatic (P7), and late-symptomatic (P10) 
time points (Figure 2, C–F). Two Uba1 splice variants are gener-
ated with unique first exons Uba1a and Uba1b (Figure 2C). Quan-
tification of relative expression levels of Uba1a and Uba1b in SMA 
and control spinal cords at P3 and P7 showed no significant dif-
ferences between the genotypes (Figure 2, D and E). In contrast, 
there was a significant reduction in relative expression levels of 
Uba1a (but not Uba1b) and a significant alteration in the ratio of 
Uba1a to Uba1b in SMA mice at P10 (Figure 2F). Thus, dysregula-
tion of Uba1 splicing may contribute to the alterations in UBA1 
protein levels observed in SMA, with the disruption in splicing in 
spinal cord temporally correlating with the reduction in UBA1 
protein levels in spinal cord (see Figure 1K). Taken together with 
data showing UBA1 subcellular redistribution and Uba1-SMN 
interaction, these findings suggest that SMN-dependent regula-
tion of UBA1 and its disruption in SMA is a complex process, 
with combinatorial effects of disruption to multiple regulatory 
pathways likely to be responsible.
Suppression of UBA1 is sufficient to induce motor neuron pathology in 
vivo. Although suppression of UBA1 and disruption of ubiquitin 
homeostasis were robust correlates of neuromuscular pathol-
ogy in SMA, it remained unclear whether these changes directly 
contributed to disease pathogenesis. To examine this possibility, 
we designed experiments to suppress uba1 in zebrafish, an acces-
sible model system to assess the effects of genetic manipulations 
on motor neuron stability (23, 33). Uba1 expression was targeted 
using an antisense Morpholino oligonucleotide (MO) designed 
against the translational start codon of the uba1 gene. Embry-
os were injected with either 4 ng or 6 ng of MO and examined 
34 hours after fertilization. Levels of UBA1 protein were robustly 
reduced in fish treated at both doses (Supplemental Figure 4A). 
Suppression of uba1 using MO had no effect on the gross develop-
ment of motor neurons in the spinal cord (Figure 3A). However, 
uba1 suppression did lead to a profound, dose-dependent disrup-
tion of motor axon outgrowth and branching. Whereas the vast 
majority of axons in control animals showed a simple, unbranched 
morphology, axons in both 4 ng and 6 ng MO–injected animals 
revealed grossly abnormal branching patterns (Figure 3, A and B). 
The percentage of motor axons with branching abnormalities (see 
Supplemental Figure 4B) increased from less than 5% in controls 
to approximately 50% in 4 ng MO animals and approximately 75% 
in 6 ng MO animals (Figure 3C). Importantly, these findings phe-
nocopied branching defects previously reported in zebrafish mod-
els of SMA (23, 33).
To confirm these findings using pharmacological suppression of 
UBA1, we treated zebrafish with UBEI-41, a cell-permeable phar-
macological UBA1 inhibitor (34). Inhibition of UBA1 revealed 
a similar, dose-dependent disruption of motor axon branching 
(Figure 3, D and E). At a dose of 10 μM UBEI-41, the majority of 
motor nerve abnormalities were due to aberrant axonal branching 
(data not shown). At 50 μM, however, approximately half of the 
motor nerve abnormalities observed (47.2%) were a result of aberrant 
nerve branching, with the remaining motor nerves revealing a more 
severe phenotype: truncated or missing motor axons (Figure 3D). 
Once again, these pathological events phenocopied motor axon 
defects observed in zebrafish models of SMA (23, 33). Thus, sup-
pression of uba1 was sufficient to phenocopy SMA-like motor 
neuron pathology in vivo. In addition to the observed motor axon 
defects, uba1 suppression led to body axis defects in zebrafish, 
both following UBEI-41 treatment and following MO treatment 
(data not shown). However, the viability of the fish was not com-
promised, as there was not a significant increase in the number of 
fish dying after uba1 suppression.
SMN-dependent suppression of UBA1 leads to accumulation of 
β-catenin. Given that UBA1 is a key component of ubiquitination 
pathways through which substrate proteins are “tagged” for tar-
geting to the proteasome, we therefore wanted to identify spe-
cific substrate proteins affected as a downstream consequence 
of the disruption to ubiquitin homeostasis in SMA. Perturba-
tions in ubiquitin pathways are often associated with a failure to 
degrade target proteins, resulting in a characteristic accumula-
tion within the cell. Reexamination of our original proteomics 
data set revealed that β-catenin levels were robustly increased, by 
more than 400%, in SMA mice (Table 1 and Supplemental Tables 
1 and 2). Examination of β-catenin levels in freshly prepared 
synaptosomes from control (Smn+/+ SMN2tg/tg), heterozygous 
(Smn–/+ SMN2tg/tg) and homozygous (Smn–/– SMN2tg/tg) severe SMA 
mice confirmed that increased levels of β-catenin corresponded 
to reduced levels of SMN protein in a dose-dependent manner 
(Figure 4A). β-catenin levels were also significantly increased in the 
spinal cords of Taiwanese SMA mice (Figure 4B and Supplemen-
tal Figure 6). Alongside changes in β-catenin levels, levels of stabi-
lized β-catenin (ABC) were reduced in the spinal cord (Figure 4C 
and Supplemental Figure 5), and levels of transcription factor 4 
(TCF-4), a key β-catenin–interacting protein required for activa-
tion of downstream response genes (35), were also significantly 
reduced (Figure 4D and Supplemental Figure 5). Importantly, 
β-catenin protein levels in muscle biopsy samples from SMA 
patients suggested that elevated levels were also a major feature 
of neuromuscular pathology in human patients (Figure 4I).
To confirm that increased levels of β-catenin were occurring 
downstream of perturbations in UBA1, we examined global 
β-catenin levels in zebrafish treated with 4 ng or 6 ng MO against 
uba1. β-Catenin levels were increased in a dose-dependent man-
ner, reaching approximately 250% of control levels in zebrafish 
treated with 6 ng MO against uba1 (Figure 4E). To further con-
firm a link between UBA1 levels and the regulation of β-catenin in 
neurons, cultures of primary hippocampal neurons and NSC-34 
motor neuron–like cells (36) were exposed to the UBA1 inhibitor 
UBEI-41 for 2 hours. UBEI-41 treatment led to a rapid and sig-
nificant increase in levels of β-catenin in hippocampal neurons 
(∼50%; Figure 4F), with an even more robust increase in β-catenin 
levels observed in NSC-34 cells (∼90%; Figure 4F), suggesting that 
motor neurons were particularly susceptible to suppression of 
UBA1. To establish whether increased levels of β-catenin protein 
led to a corresponding increase in β-catenin signaling activity, 
we performed luciferase activity reporter experiments. β-Catenin 
activity was significantly increased in NSC-34 cells treated with 
UBEI-41 for 2 hours (Figure 4G). In order to ascertain whether 
such changes in β-catenin signaling activity could explain changes 
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Figure 4
β-Catenin is a downstream target of UBA1 and accumulates in SMA. (A) β-Catenin and SMN protein in spinal cord of severe SMA, heterozygous 
(Het), and littermate (con) mice at P5 (tubulin: loading control). (B–D) β-Catenin was increased in P10 Taiwanese SMA mouse spinal cord (n = 3 
control mice, n = 4 SMA; unpaired 2-tailed t test), whereas stabilized β-catenin (ABC; C) and TCF-4, a β-catenin interacting protein required for 
activation (D), were both reduced (n = 3 CON, n = 3 SMA). (E) Increased β-catenin protein in zebrafish injected with 4 ng or 6 ng of a uba1 MO 
48 hours after fertilization. (F) Increased β-catenin in rat hippocampal neurons and a motor neuron cell line (NSC-34) treated with 50 μM UBEI-41 
(ANOVA with Tukey’s post-hoc test; n = 12 coverslips DMSO, n = 15 UBEI-41 hippocampal; n = 19 DMSO, n = 18 UBEI-41 NSC-34). (G) Increased 
β-catenin signaling activity in NSC-34 cells treated with 50 μM UBEI-41 measured with a luciferase reporter construct (n = 3 coverslips per treat-
ment). (H) The majority of proteins modified in SMA synapses (66 out of 115 analyzed; see Supplemental Tables 1 and 2) are known β-catenin 
target genes identified by ChIP-Seq analyses. (I) Increased β-catenin protein in muscle biopsies from 3 human SMA patients (pooled data on 
right of dotted line). (J) Western blots for β-catenin (left panel; green) and ubiquitin (right panel; red) from co-IP experiments on synaptic extracts 
from 2 WT mice (L, ladder; M1, mouse 1; M2, mouse 2). Immunoblotting on the bound extract revealed the presence of ubiquitinated β-catenin 
(upper arrow). *P < 0.05; **P < 0.01; ***P < 0.001.
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in levels of other proteins found to be altered in SMA synap-
tosomes, we compared our proteomics data set to published 
β-catenin ChIP-Seq data revealing potential downstream targets 
of β-catenin (37). This analysis revealed that the majority of pro-
teins modified in SMA synapses (66 out of 115 analyzed) were 
also present in the ChIP-seq data (Figure 4H), indicative of them 
being putative β-catenin targets.
β-catenin is a known target of the ubiquitin-proteasome system 
(38), but we wanted to confirm that β-catenin was being ubiquiti-
nated in neurons. We therefore performed IP experiments on pro-
tein isolated from synaptosomes generated from WT mice (as in 
our initial proteomics screen, where increased levels of β-catenin 
were identified) using either β-catenin beads or pan-ubiquitin 
beads. Western blotting with antibodies against β-catenin and 
ubiquitin demonstrated that ubiquitinated forms of β-catenin were 
present in neurons and their synaptic compartments (Figure 4J).
Inhibition of β-catenin signaling reverses UBA1-dependent destabiliza-
tion of motor neurons. To test whether the UBA1-dependent effects on 
motor nerve branching we observed previously were mediated by 
downstream effects on β-catenin signaling pathways, we exposed 
zebrafish embryos treated with the UBA1 inhibitor UBEI-41 
to quercetin, a plant-derived flavonoid that robustly inhibits 
β-catenin signaling pathways by disrupting transcriptional activity 
of the β-catenin–Tcf complex (39–41). Treatment of fish with motor 
neuron defects resulting from the addition of 50 μM UBEI-41 
with 25 μM or 50 μM quercetin revealed a dose-dependent res-
cue of the motor axon branching phenotype (Figure 5, A and B). 
Strikingly, in the fish treated with 50 μM quercetin, the number 
of abnormal motor nerves was reduced to that observed in control 
fish not exposed to the UBA1 inhibitor. Treatment with 50 μM 
quercetin also ameliorated motor axon branching defects in zebrafish 
treated with MO against uba1 (data not shown). Thus, motor 
nerve abnormalities induced by inhibition of uba1 in zebrafish 
were fully rescued by simultaneous inhibition of β-catenin sig-
naling. In addition to the motor nerve disruptions observed, we 
noted that exposure to UBEI-41 caused dose-dependent alteration 
of the gross morphology of zebrafish embryos, manifesting as a 
bent body axis (Figure 5C). These deficits were also corrected by 
treatment with quercetin (Figure 5C).
Inhibition of β-catenin signaling ameliorates neuromuscular pathology 
in zebrafish and Drosophila models of SMA. Given that pharmacologi-
cal inhibition of β-catenin signaling with quercetin was sufficient 
to block motor axon defects resulting from targeting of UBA1, 
we next wanted to know whether pharmacological inhibition of 
β-catenin signaling would have similar beneficial effects on neu-
romuscular pathology in animal models of SMA. Treatment with 
50 μM quercetin robustly and significantly reduced the incidence 
of both truncated motor axons and motor axon branching defects 
in SMA zebrafish (33), reducing levels of motor axon pathology 
back to those observed in healthy control animals (Figure 6, A–C). 
Similarly, quercetin treatment reversed morphological defects 
associated with the NMJ in a dose-dependent manner in an estab-
lished Drosophila model of SMA (31), rescuing both synaptic bou-
ton size and bouton density in the treated SMA flies (Figure 6, 
D–F). Thus, pharmacological inhibition of β-catenin signaling 
with quercetin ameliorated key markers of neuromuscular pathol-
ogy in both invertebrate and vertebrate models of SMA.
Inhibition of β-catenin signaling ameliorates neuromuscular pathology, 
but not systemic pathology in SMA mice. Finally, we wanted to establish 
whether pharmacological inhibition of β-catenin signaling with 
quercetin could have a similar effect on disease phenotype in SMA 
mice. Taiwanese SMA mice and littermate controls were treated 
with 10 mg/kg quercetin daily (i.p. injection) from birth. A parallel 
group of mice received injections of DMSO vehicle only. Treatment 
with 10 mg/kg quercetin was well tolerated by healthy littermate 
controls (an increased dose of 50 mg/kg quercetin was found to 
have toxic effects after several days of administration) and had no 
significant detrimental effect on neuromuscular function in SMA 
mice at presymptomatic ages (P3; Figure 7A). In contrast, quer-
cetin treatment significantly improved the performance of early 
and late-symptomatic SMA mice on the righting test (Figure 7A). 
Quercetin treatment ameliorated motor neuron cell body loss 
from the spinal cord (Figure 7, B and C), restored muscle fiber 
diameters of SMA mice to those of littermate control mice at late-
symptomatic stages (P11; Figure 7, E and F), and also ameliorated 
NMJ pathology, restoring the average number of axonal inputs 
in SMA mice to the same levels observed in littermate controls 
Figure 5
Rescue of uba1-dependent motor axon defects in zebrafish by phar-
macological inhibition of β-catenin signaling. (A) Representative confo-
cal micrographs showing 3 segments of Tg(hb9:gfp) zebrafish embry-
os from the trunk region. Note the severe branching phenotype of the 
motor nerves in the UBEI-41–treated animal. This phenotype was res-
cued by quercetin treatment. Scale bar: 30 μm. (B) Dose-dependent 
increase in numbers of aberrant motor axons in the UBEI-41–treated 
group compared with DMSO controls. This phenotype was rescued 
by quercetin in a dose-dependent manner (DMSO controls: n = 331 
nerves, n = 14 animals; 10 μM UBEI-41: n = 258, n = 11; 50 μM UBEI-41 
n = 280, n = 12; 50 μM UBEI-41 + 25 μM quercetin: n = 143, n = 6; 50 μM 
UBEI-41 + 50 μM quercetin: n = 168, n = 7; Kruskal-Wallis test with 
Dunn’s post hoc test). (C) Representative overview images showing 
body axis defects in zebrafish embryos after UBEI-41 treatment com-
pared with DMSO controls. Note the rescue of this gross phenotype 
following application of 50 μM quercetin. ***P < 0.001.
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(Figure 7, G and H). Thus, as we previously observed in zebrafish 
and Drosophila models, pharmacological inhibition of β-catenin 
signaling with quercetin ameliorates neuromuscular dysfunction 
and pathology in SMA mice.
Quercetin-treated mice often appeared much healthier than 
their DMSO-treated counterparts at late symptomatic stages 
(Figure 7D), but treatment with quercetin did not increase sur-
vival (Figure 7I) or average body weight (Supplemental Figure 6). 
Examination of quercetin-treated mice postmortem revealed the 
presence of widespread gross organ defects previously reported in 
SMA mice (Figure 7J), where systemic pathology is known to target 
organs including the heart and liver (10, 14, 16). In order to exam-
ine the possible causes of this failure to ameliorate nonneuromus-
cular, systemic pathology (even when quercetin was administered 
systemically via i.p. injection), we quantified UBA1 and β-catenin 
levels in the heart and liver from late-symptomatic Taiwanese SMA 
mice and littermate controls. Levels of UBA1 in the heart and liver 
were reduced in SMA mice to a level similar to that observed in 
spinal cord (Figure 7K). Surprisingly, however, β-catenin levels 
were not significantly modified in the heart and liver (Figure 7H). 
Thus, perturbations in β-catenin signaling pathways occurring 
downstream of disrupted ubiquitin homeostasis were restricted 
to the neuromuscular system and were not repeated in nonneu-
romuscular organs. This suggests that distinct mechanisms drive 
pathology in the neuromuscular system compared with other tis-
sue and organ systems in SMA and may explain, at least in part, 
why pharmacological inhibition of β-catenin selectively amelio-
rated neuromuscular pathology in SMA mice.
Discussion
The studies described here were initiated to identify novel regu-
lators of neuromuscular pathology in SMA. Using rodent, Dro-
sophila, and zebrafish SMA models, we have revealed an important 
role for ubiquitin homeostasis, mediated largely via modifica-
tions in levels of UBA1. Suppression of UBA1 in SMA is likely to 
result from a complex series of events, including disruptions in 
both splicing of Uba1 mRNA and physical interactions between 
SMN and UBA1 protein in the cytoplasm. Experimental down-
regulation of UBA1 expression was sufficient to generate motor 
neuron pathology in vivo, phenocopying the severe axonal defects 
Figure 6
Amelioration of neuromuscular pathology in zebrafish and Drosophila models of SMA following pharmacological inhibition of β-catenin signaling. 
(A) Representative confocal micrographs of motor axons growing out from the spinal cord in a SMA zebrafish 34 hours after fertilization (top panel) 
as well as an SMA zebrafish treated with 50 μM quercetin (bottom panel). Note the abnormal outgrowth and branching of motor axons in SMA 
zebrafish absent in the SMA zebrafish treated with quercetin. Scale bar: 100 μm. (B and C) Significant improvement in the number of truncated 
motor axons (B) and abnormally branched motor axons (C) in SMA zebrafish treated with 50 μM quercetin (Kruskal-Wallis test with Dunn’s post 
hoc test; n = 31 animals, control; n = 32 SMA; n = 30 SMA + 50 μM quercetin). (D) Representative confocal micrographs of NMJs in WT Drosophila 
(w1118), SMA Drosophila without quercetin, and SMA Drosophila fed 50 μM quercetin. NMJs were stained with anti-HRP to visualize axons and 
anticysteine string protein to identify synaptic boutons. Scale bar: 10 μm. (E and F) Feeding SMA Drosophila 50 μM quercetin restored bouton 
size (E) and rescued synaptic overgrowth (F) (n = 8 larvae per treatment; ANOVA with Tukey’s post test). *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 7
Pharmacological inhibition of β-catenin ameliorates neuromuscular, but not systemic, pathology in SMA mice. (A) Significant improvement on the 
righting test in early (P6) and late-symptomatic (P9) Taiwanese SMA mice (KO) treated with 10 mg/kg quercetin (Kruskal-Wallis test with Dunn’s 
post hoc; P3, n = 30 tests Het; n = 27 KO; n = 21 KOQ; P6, n = 31, Het; n = 28 KO; n = 27 KOQ; P9, n = 32, Het; n = 27 KO; n = 36 KOQ). (B and C) 
Reduced motor neuron loss from spinal cord of quercetin-treated SMA mice at P10. (D) Untreated (left) and a quercetin-treated (right) SMA mice 
at P10. (E and F) Amelioration of skeletal muscle fibre atrophy in the levator auris longus (LAL) muscle of quercetin-treated SMA mice at P10 (n = 
8 muscles Het, n = 9 KO, n = 4 KOQ). (G and H) Reduced NMJ pathology (average number of axonal inputs per NMJ; multiply innervated NMJs 
are indicated by arrows) in the LAL muscle of quercetin-treated SMA mice at P10 (n = 8 muscles Het, n = 9 KO, n = 4 KOQ). (I) Survival curve 
for quercetin-treated SMA mice showing no significant difference compared with DMSO-treated controls (P = 0.9897, χ2 test; n = 10 mice DMSO; 
n = 13 quercetin). (J) Hearts (top) and livers (bottom) from control, SMA (KO DMSO), and quercetin-treated SMA (KO quercetin) mice at P10 show-
ing no improvement in gross pathology. (K and L) UBA1 levels were reduced in all tissues from SMA mice at P10,but β-catenin levels were only 
correspondingly increased in spinal cord (n > 3 mice per genotype; ANOVA with Tukey’s post-hoc). Scale bars: 200 μm (B), 25 μm (E and G), 5 mm 
(J). *P < 0.05; **P < 0.01; ***P < 0.001.
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cological targeting in vivo. It should be noted, however, that quer-
cetin is a pleiotropic flavonoid and as such is capable of modify-
ing targets alongside β-catenin pathways. Nevertheless, targeting 
β-catenin signaling pathways (in addition to other pathways mod-
erated by quercetin) during the early stages of disease may repre-
sent an attractive therapeutic option for stabilizing the neuromus-
cular system in SMA, and possibly also related conditions.
Given that β-catenin is such a well-established target for the 
ubiquitin-proteasome system and the magnitude of changes 
in β-catenin pathways observed in the neuromuscular system 
in SMA mice, it was surprising to find that quercetin treatment 
did not target systemic pathology in SMA. However, our finding 
that β-catenin signaling pathways remained stable in tissues and 
organs outside the neuromuscular system in SMA mice provides 
an explanation for this result and serves to highlight an underap-
preciated complexity in molecular pathways underlying disease 
pathogenesis in SMA. These findings also add further significant 
support to the hypothesis that SMA is a multisystem disorder (10) 
and add an additional layer of complexity with regards to distinct 
molecular pathways driving pathology in different tissues. More-
over, they further highlight the likely requirement to deliver thera-
peutics targeting either the SMN1 or SMN2 gene systemically in 
order to fully rescue SMA symptoms (14).
Methods
Mice, human patient samples, and study approvals. Severe (Smn–/– SMN2tg/tg; 
ref. 45) and Taiwanese (Smn–/– SMN2tg/0; refs. 32, 46) SMA mice, both on a 
congenic FVB background, were obtained from Jackson Laboratories and 
maintained at the University of Edinburgh. Littermate animals either WT 
or heterozygous for Smn (Smn+/+ or Smn+/–) were used for controls. Mice 
were bred and sacrificed under license from the United Kingdom Home 
Office, and were genotyped using standard PCR methods (5, 32).
Skeletal muscle (quadriceps femoris) biopsy samples were obtained from 
2 different biobanks in Italy (Fondazione IRCCS Istituto Neurologico 
Carlo Besta, Milan; Fondazione Ospedale Maggiore Policlinico Mangia-
galli e Regina Elena, IRCCS, Milan) through EuroBioBank (http://www.
eurobiobank.org/). Biopsies were obtained from 3 type II/III SMA patients 
(aged between 3 and 25 years old), with a confirmed homozygous deletion 
of the SMN1 gene confirming a genetic diagnosis of SMA (47). Three age-
matched control samples were also obtained; these were genetically con-
firmed to have no mutations in the SMN1 gene.
iTRAQ quantitative proteomics. iTRAQ proteomics was performed on 
freshly isolated synaptosome preparations from the hippocampus of P1 
Smn–/– SMN2tg/tg (severe) and Smn+/+ SMN2tg/tg (control) mice (n = 9 mice 
per genotype), as previously described (48). Samples were run in duplicate 
using the 4-plex system (114 and 116, SMA; 115 and 117, control). Only 
proteins identified by 2 or more unique peptides were taken forward for 
subsequent analysis. A stringent cut-off threshold of 20% change (increase 
or decrease) was used to identify proteins with modified expression. In sili-
co functional pathways analyses were performed using Ingenuity Pathway 
Analysis software (48).
Western blot analyses. Quantitative Li-Cor fluorescent Western blotting 
was performed as previously described (4) using the following primary 
antibodies: SMN, synaptophysin (Santa Cruz Biotechnology Inc.); SMN, 
β-catenin (BD Biosciences); βIII tubulin, UBA1 (Abcam); histone H2B, 
active motif; Cox IV (MitoSciences); Ubiquitin (UBI1) (Millipore). Where 
required, 2 independent sets of measurements were produced per sample 
in order to minimize the effects of different laser scan intensities on the 
resulting data (e.g. where strong and weak bands were being measured on 
the same gel). Standard Western blotting was performed using the fol-
previously reported in zebrafish models of SMA (33). We identi-
fied β-catenin as a downstream target of UBA1/ubiquitination 
pathways in the neuromuscular system and showed a robust 
accumulation of β-catenin in SMA. Pharmacological inhibition 
of β-catenin signaling using quercetin ameliorated neuromuscu-
lar pathology caused by targeting of UBA1 and in zebrafish, Dro-
sophila, and mouse models of SMA. Whereas disruption of UBA1 
was found to occur across a range of neuronal and nonneuronal 
organs in SMA mice, surprisingly, we found that downstream dis-
ruption of β-catenin was restricted to the neuromuscular system 
and was not responsible for regulating SMN-dependent pathology 
in other tissues and organs. Our findings provide experimental 
evidence directly linking the regulation of ubiquitin homeostasis 
and β-catenin signaling to neuromuscular pathology in SMA and 
also reveal fundamental molecular differences between pathways 
underlying neuromuscular and systemic pathology in SMA.
Although it is known that SMN protein interacts with the ubiquitin- 
proteasome system in order to regulate its own stability (28–30), 
our study markedly extends our understanding of the importance 
of these interactions to include a direct role for dysregulation of 
ubiquitin homeostasis in the pathogenesis of SMA. When taken 
together with human genetic data showing that mutations in UBA1 
cause pathological changes similar to those found in SMN-depen-
dent SMA (22), our findings suggest that perturbations in ubiqui-
tin homeostasis, and UBA1 in particular, may represent a common 
molecular pathway underlying neuromuscular pathology across 
genetically distinct forms of the disease. Moreover, the finding 
that perturbations in ubiquitin homeostasis in response to SMN 
deficiency as well as dysregulation of β-catenin downstream of per-
turbations in UBA1 are evolutionarily conserved among mouse, 
zebrafish and Drosophila models suggests that regulation of ubiq-
uitin homeostasis represents a core response to low levels of func-
tional SMN protein. Our finding that loss of UBA1 protein in SMA 
likely resulted from perturbations to both Uba1 mRNA missplicing 
and disruption to physical interactions between SMN and UBA1 as 
well as modifications to normal postnatal subcellular redistribu-
tion of the protein suggests that molecular pathways responsible 
for controlling UBA1 levels in vivo are complex and multifaceted. 
However, the demonstration of interactions between UBA1 and 
SMN provides additional evidence to support the hypothesis that 
interactions between SMN and ubiquitination pathways are key 
for the normal form and function of the neuromuscular system, 
not only with regards to the regulation of SMN protein stability 
(28–30), but also with respect to modulating ubiquitin homeosta-
sis and cell viability.
Our identification of β-catenin as a key downstream target 
of ubiquitin pathways disrupted in SMA provides mechanistic 
insights into the pathways through which defects in ubiquitin 
homeostasis are transferred into pathological changes in the neu-
romuscular system. Although these pathways have not previously 
been linked to neuromuscular pathology in SMA, β-catenin signal-
ing pathways are known to play an important role in regulating 
motor neuron differentiation and stability, including regulating 
synaptic structure and function (42–44). Interestingly, Li and col-
leagues previously reported that motor neuron differentiation is 
regulated by retrograde signaling through β-catenin from skeletal 
muscle (43). Our demonstration of robust amelioration of neuro-
muscular pathology in zebrafish, Drosophila, and mouse models 
of SMA treated with quercetin highlights the fact that β-catenin 
pathways in the neuromuscular system are amenable to pharma-
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To examine levels of mono- and polyubiquitinated proteins in SMA 
skeletal muscle, we used wandering third instar larvae null for SMN (31). 
Ubiquitinated proteins were detected using an anti–mono- and polyubiq-
uitinylated primary antibody (1:100; FK2; BML-PW8110, Enzo Life Sci-
ences). Nuclei were visualized using Hoechst (1:500). For the quercetin 
rescue experiments, SMN or WT flies (w1118) were maintained on a diet of 
Drosophila Quick Mix Medium (Blades Biological) containing 0 to 50 μM 
quercetin hydrate (Sigma-Aldrich). Third instar smn null larvae were dis-
sected and fixed. NMJ were visualized using Dylight 649–conjugated anti-
HRP (1:200, Jackson ImmunoResearch), and the presynaptic marker cys-
teine string protein (1:200, Developmental Studies Hybridoma Bank) was 
used to identify synaptic boutons. The average number of boutons (nor-
malized to muscle area) per NMJ at muscle 6/7 was calculated. Maximum 
bouton diameters were averaged per NMJ at muscle 6/7.
UBEI-41 in vitro experiments. Primary rat hippocampal cultures were estab-
lished from E18 Sprague-Dawley rat embryos as previously described (52). 
NSC-34 cells (36) were generated from existing stocks held at the Univer-
sity of Edinburgh. UBEI-41 (Biogenova), a cell-permeable UBA1 inhibitor 
with an IC50 of approximately 5 μM, was added to the culture medium 
(50 μM) for 2 hours. β-catenin levels (and β-III tubulin loading control 
levels) were quantified using fluorescent Western blotting (see above) with 
anti–β-catenin (1:1000; BD Transduction Laboratories) and anti–β-III 
tubulin (1:1600; Abcam) primary antibodies.
To quantify β-catenin activity, NSC-34 cells were transiently trans-
fected with a TOPflash reporter plasmid containing a luciferase reporter 
under the control of 3 copies of the TCF/LEF-binding element upstream 
of the thymidine kinase minimal reporter, specifically regulated by Wnt/
β-catenin signaling. NSC-34 cells were seeded in a 24-well plate, and at 
70%–80% confluency, cells were transfected, in triplicate, with 350 ng 
TOPflash plasmid using Lipofectamine 2000 (Invitrogen). To control for 
transfection efficiency, 20 ng phTKRenilla luciferase plasmid was used. 
Cells were treated with 50 μM UBEI-41 28 hours after transfection. Trans-
fected samples were analyzed for firefly and Renilla luciferase activities 
30 hours after transfection using the Dual-Luciferase Reporter Assay 
System (Promega) and measured using a FLUOstar OPTIMA Microplate 
Reader (BMG LABTECH). All values were corrected to blank wells and nor-
malized to expression from the phTKRenilla plasmid.
Zebrafish uba1 and smn knockdown. An antisense MO was designed against 
the translational start codon of the uba1 gene (Gene Tools LLC): 5′-ACAGC-
GGCGAGCTGGACATCGTTTC-3′. The previously published smn-MO was 
designed against the 5′ start sequence of the smn gene (Gene Tools LLC.); 
5′-CGACATCTTCTGCACCATTGGC-3′ (33). Zebrafish embryos were 
injected between the 1- and 4-cell stage. For direct evaluation of motor 
axon phenotype, we used embryos obtained from crossing TL/EK WT and 
Tg(mnx:GFP)ml2 transgenic animals (53). Embryos were injected with either 
4 or 6 ng of uba1-MO or 4 ng of smn-MO in aqueous solution containing 
0.05% phenol red and 0.05% rhodamine-dextran. Six hours after injection, 
embryos were sorted according to homogeneity of rhodamine fluores-
cence, reflecting equal distribution of the injected MO solution. Quercetin 
(Sigma-Aldrich) treatment was performed at 6 hpf. In brief, quercetin solu-
tion (in DMSO) or DMSO (Sigma-Aldrich) was added to buffered embryo 
medium (final volume: 2 μlDMSO/mlmedium) to obtain a final concentration of 
50 μM. For immunostaining, fish (34 hpf) were dechorionated and fixed in 
4% PFA overnight, dehydrated in methanol, rehydrated, and washed in PBS. 
After collagenase treatment (1 μg/ml; C-9891, Sigma-Aldrich) for 10 min-
utes at room temperature, embryos were blocked in PBST plus 1% DMSO 
plus 10% FCS, followed by overnight incubation in 500 μl blocking solu-
tion containing monoclonal mouse anti-zebrafish Synaptotagmin (znp-1) 
antibody (1:300; Developmental Studies Hybridoma Bank). After washing, 
fish were incubated in donkey anti-mouse secondary antibody labeled with 
lowing primary antibodies: SMN: all MANSMA antibodies (49); gemin5: 
GEM5M, GEM5O, GEM5Q. All protein levels reported on graphs repre-
sent arbitrary fluorescence units.
IP experiments. IP was performed as previously described (50). Briefly, 
protein was extracted in NP-40 lysis buffer (Novex; Life Technologies) con-
taining 1% protease inhibitor cocktail (Roche). Following centrifugation 
at 16000 g, the supernatant was added to Dynabead protein G anti-mouse 
beads bound with preselected antibodies (β-catenin, UCHL1, and SMN) 
and subjected to quantitative fluorescent immunoblotting.
For Gemin5 IP experiments, anti-mouse Pan Ig–coated magnetic beads 
(50 μl) (Dynal) were washed in 4% BSA/PBS and incubated for 30 minutes 
with a monoclonal SMN antibody (10 μg; MANSMA12), GEM5M anti-
body against Gemin 5, or 150-kDa neurofilament antibodies as a control. 
After washing, beads were incubated with synaptosome extract for 1 hour, 
followed by washing 5 times with PBS. Proteins bound to beads were eluted 
by boiling in 2× SDS sample buffer, as previously described (51).
RNA extraction, qPCR, and Uba1 splicing assays. mRNA was extracted 
from synaptosomes using an RNeasy Microkit (QIAGEN). Samples were 
checked for DNA contamination, and concentration was determined using 
a nanodrop spectrophotometer (Thermo Scientific). Quantitative RT-PCR 
(qRT–PCR) was carried out using a SYBR Green 1-step qRT-PCR Kit 
(Invitrogen) on a Model 7700 instrument (Applied Biosystems). The fol-
lowing primers were used: Uba1, forward GAGCGGGGACTTTGTCTCCT; 
Uba1, reverse CTTTGACCTGACTGACGAT; Fth1, forward AATTTCTT-
GACCCACTGGTGCACT; Fth1, reverse TCGAATCGAGAGTAGTGGCA-
CA; Mapt, forward GATTCTCGTGAGGTTGACGACT; Mapt, reverse TAC-
GGACGAAGAAGCCGACATT.
mRNA was extracted from spinal cord using an RNeasy Microkit (QIAGEN). 
Samples were checked for DNA contamination, and concentration was 
determined using a nanodrop spectrophotometer (Thermo Scientific). 
RNA integrity was checked visually by resolution on agarose gels. cDNA was 
made from 2 μg RNA using the High Capacity cDNA Reverse Transcription 
Kit (Invitrogen). Primers were designed that amplified the 2 mouse Uba1 
transcripts, using a unique forward primer with a common reverse primer 
(Uba1a, forward GCTTGTCTCCAGAAGGAAGG; Uba1b, forward CTT-
GACTTCGGCTCCTTGAG; Uba1a/Uba1b, reverse CACTGAGGACACTTC-
GGACA). Two mouse housekeeping genes (GAPDH and OAZ1) were 
used (GAPDH, forward CGTCCCGTAGACAAAATGGT; GAPDH, reverse 
GAATTTGCCGTGAGTGGAGT; OAZ1, forward ATCCTCAACAGCCACT-
GCTT; OAZ1, reverse CGGACCCAGGTTACTACAGC). For real-time detec-
tion, an ABI7000 machine (Applied Biosystems) was used. cDNA was ampli-
fied using 0.5 to 1 μM primer with the DyNAmo Flash SYBR Green qPCR kit 
(Thermo Scientific) and using a standard PCR program with amplification 
at 60°C. Each cDNA sample was amplified in triplicate with all primer pairs. 
Experimental CT values for each sample were compared, and samples rep-
resenting CT minimum for each primer pair were identified. The equation 
where raw data = 1+E(Ctmin-Ct) was used to determine relative expression levels 
for each sample. Raw values obtained for Uba1a and Uba1b were normalized 
using the geometric mean of the 2 housekeeping genes.
Drosophila experiments. To examine localization of SMN, pan-neural expres-
sion of UAS-YFP-dSMN was driven by Elav-Gal4C155. MHC82-Gal4C crossed 
to UAS-YFP-dSMN flies were used as controls. Wandering third instar larvae 
were dissected in PBS and fixed for 10 minutes in 4% paraformaldehyde. 
GFP staining at NMJs was detected by blocking larval fillets in 3% BSA, 
0.1% Triton X-100 in PBS overnight, incubating in primary antibody, 1:400 
(chicken anti-GFP; A10262, Invitrogen), followed by secondary antibody, 
1:250 (goat anti-chicken Alexa Fluor 488; A11039, Invitrogen). NMJs and 
motor neurons were visualized with Dylight 649–conjugated anti-HRP, 
1:200 (Jackson ImmunoResearch). Images were acquired on a Zeiss LSM510 
Meta using a Pan Apochromat 63× 1.4 NA oil immersion objective.
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approved by the internal ethics committee at the University of Edinburgh 
and were performed under the authority of relevant project and personal 
licenses from the United Kingdom home office.
Statistics. All graphs are shown as mean ± SEM. All statistical analyses 
were completed using GraphPad Prism software. P < 0.05 was considered 
statistically significant for all analyses.
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Alexa Fluor 488 (1:200; Invitrogen). Microscopical analysis was performed 
in 80% glycerol on micro slides using an Axioskop 2 fluorescence micro-
scope (Zeiss). The length of each of the first 10 motor axons behind the 
yolk was analyzed and evaluated, as was the extent of abnormal branching 
(Supplemental Figure 4).
Zebrafish UBEI-41 experiments. UBEI-41 (BioGenova), on its own or with 
quercetin (Sigma-Aldrich), was dissolved in DMSO and added at 6 hpf 
to Tg(mnx:GFP)ml2 embryos. The final amount of DMSO in the test 
groups was always 2 μl/ml in buffered embryo medium. Western blots 
were performed using the following antibodies: anti–β-actin (zebrafish) 
(rabbit polyclonal, 1:1,000; Anaspec); anti-Uba1 (mouse monoclonal, 
1:1,000; Santa Cruz Biotechnology Inc.); anti–rabbit-HRP (1:10,000; GE 
Healthcare); anti–mouse-HRP (1:10,000; Sigma-Aldrich); anti–β-catenin 
(polyclonal rabbit, 1:1,000, C2206; Sigma-Aldrich). At 27 hpf, embryos 
were dechorionated, fixed in 4% PFA for 2 hours, and mounted in 70% 
glycerol. Motor nerves were assessed for abnormal trajectories using a Zeiss 
Axioscope A1 fluorescence microscope, and image stacks were taken using 
a Zeiss LSM710. For each embryo, 24 axons in 12 segments were analyzed. 
The observer was always blinded to the treatment.
SMA mouse quercetin experiments. Taiwanese mice and littermate controls 
were dosed daily with either 10 mg/kg quercetin (Sigma-Aldrich) or DMSO 
alone for a vehicle-only control via intraperitoneal injection. Mice were ran-
domly assigned to treatment groups. Righting reflex tests were performed 
in order to assess neuromuscular function, as previously described (54). 
Muscle fibre diameter measurements were taken from phase-contrast 
micrographs of teased muscle fiber preparations using ImageJ software, as 
previously described (4). Motor neuron cell body counts were performed 
as previously described (32). NMJ pathology was assessed on whole-mount 
preparations of levator auris longus muscles, as described previously (5). 
Kaplan-Meier survival analyses were performed on DMSO and quercetin-
treated mice as previously described (55). Organs were dissected and either 
fixed in 4% paraformaldehyde overnight for subsequent imaging, or were 
prepared for quantitative Western blotting.
Study approval. All required ethical approvals to acquire and distribute 
human patient tissue samples were obtained by the host biobanks. Tissue 
was provided in an anonymous fashion, with no identifying details apart 
from the age, sex, and genetic status of the patient. All animal studies were 
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